造血干细胞移植治疗多发性骨髓瘤

[1]	李娟,赵莹,罗绍凯,等.223例新诊断多发性骨髓瘤临床特点及疗效分析[J].中华医学杂志,2008,88(30): 2140-2143.
[2]	JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics [J].CA Cancer J Clin,2011,61:69-90.
[3]	RICHARDSON P,WELLER E,LONIAL S,et al.Lenalidomide,bortezomib,and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma [J].Blood,2010,116: 679-686.
[4]	BARLOGIE B,HALL R,ZANDER A,et al.High-dose melphalan with autologous bone marrow transplantation for multiple myeloma [J].Blood,1986,67:1298-301.
[5]	ATTAL M,HAROUSSEAU J L,STOPPA A M,et al.A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.Intergroupe Francais du Myelome [J].N Engl J Med,1996,335:91-97.
[6]	ANDERSON K C,ALSINA M,BENSINGER W,et al.NCCN clinical practice guidelines in oncology: multiple myeloma [J].J Natl Compr Canc Netw,2009,7: 908-942.
[7]	ABDELKEFI A,LADEB S,TOMAN L,et al.Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multi-center randomized clinical trial [J].Blood,2008,111:1805-1810.
[8]	曾丽金,李娟,赵莹,等.移植前不同诱导治疗效果对多发性骨髓瘤患者移植后疗效的影响[J].中华血液学杂志,2010,31(2):119-121.
[9]	LAHUERTA J J,MATEOS M V,MARTINEZ L J,et al.Influence of pre- and post- transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival [J].J Clin Oncol,2008,26:5775-5782.
[10]	BENSON D M J R,PANZNER K HAMADANI M,et al.Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma [J].Leuk lymphoma,2010,51:243-251.
[11]	刘俊茹,李娟,陈媚,等.大剂量环磷酰胺联合粒细胞集落刺激因子动员多发性骨髓瘤造血干细胞的价值研究[J].中国实用内科杂志,2011,31(7): 530-532.
[12]	GIRALT S,STADTMAUER E A,HAROUSSEAU J L,et al.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) [J].Leukemia,2009,23:1904-1912.
[13]	LAHUERTA J J,GRANDE C,MARTINEZ L J,et al.Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma[J].Leuk Lymphoma,2002,43:67-74.
[14]	ROUSSEL M,MOREAU P,HUYNH A,et al.Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) [J].Blood,2010,115:32-37.
[15]	NISHIHORI T,ALEKSHUN T J,SULLIVAN D M,et al.Bortezomib followed by a phase I study of bortezomib in combination with high-dose melphalan as a preparative regimen for hematopoietic cell transplants in patients with primary refractory multiple myeloma or plasma cell leukemia[J].Biol Blood Marrow Transplant,2011,7:S200-S201.
[16]	ATTAL M,HAROUSSEAU J,FACON T,et al.Single versus double autologous stem-cell transplantation for multiple myeloma[J].N Engl J Med,2003,349: 2495-2502.
[17]	BARLOGIE B,TRICOT G J,VAN RHEE F,et al.Long-term outcome results of the first tandem auto-transplant trial for multiple myeloma[J].Br J Haematol,2006,135:158-164.
[18]	BENSINGER W,BUCKNER C,ANASETTI C,et al.Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome[J].Blood,1996,88:2787-2793.
[19]	LOKHORST H,EINSELE H,VESOLE D,et al.International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma[J].J Clin Oncol,2010,28:4521-4530.
[20]	VESOLE D H,ZHANG L,FLOMENBERG N,et al.A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97[J].Biol Blood Marrow Transplant,2009,15:83-91.
[21]	GAHRTON G,BJORKSTRAND B,IACOBELLI S,et al.Tandem autologous (AUTO-HSCT)/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus AUTO-HSCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT[J].Blood (ASH Annual Meeting Abstracts),2009,114:52-.
[22]	ROSIÑOL L,PÉREZ-SIMÓN J A,SUREDA A,et al.A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma[J].Blood,2008,112:3591-3593.
[23]	SPENCER A,PRINCE H M,ROBERTS A W,et al.Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J].J Clin Oncol,2009,27:1788-1793.